Seattle Genetics Inc., of Bothell, Wash., beat predicted sales in the third quarter of Adcetris (brentuximab vedotin) for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, chalking up $48.2 million. The company showed quarter-over-quarter growth of 11 percent.